Related Experiment Videos
Opportunities to improve the cost-effectiveness of treatment for hypertension
1Health Economics Research, Inc., Waltham, MA 02154.
Insights
Optimizing hypertension management requires careful patient selection and adherence. Cost-effectiveness hinges on factors like blood pressure levels, patient characteristics, and treatment adherence, with mild hypertension posing challenges.
Area of Science:
- Cardiovascular Medicine
- Health Economics
- Public Health Policy
Background:
- Hypertension management is a significant public health concern.
- The cost-effectiveness of hypertension treatment is influenced by numerous patient-specific and treatment-related factors.
Purpose of the Study:
- To analyze the determinants of cost-effectiveness in hypertension treatment.
- To identify strategies for improving the economic efficiency of hypertension management.
Main Methods:
- Review of factors influencing cost-effectiveness: pretreatment blood pressure, patient demographics, comorbidities, long-term control, and treatment costs.
- Analysis of cost-effectiveness for very mild hypertension (diastolic blood pressure 90-94 mm Hg).
- Identification of opportunities for enhancing cost-effectiveness in clinical practice.
Main Results:
- Treatment of very mild hypertension is generally not cost-effective, even when benefits outweigh risks.
- Key areas for improving cost-effectiveness include accurate diagnosis, enhanced patient adherence, medication de-escalation, cost-conscious clinical decisions, and practice efficiency.
Conclusions:
- Cost-effectiveness in hypertension care is highly variable and depends on a multifaceted approach.
- Future guidelines should explicitly incorporate cost-benefit analyses for tailored patient management strategies.
Abstract:
The cost-effectiveness of treatment for hypertension depends on the pretreatment level of blood pressure, age and sex of the patient, presence of other cardiovascular risk factors, long-term control of blood pressure, and the annual costs of treatment. Treatment of very mild hypertension (diastolic blood pressure, 90-94 mm Hg), even if the benefits do exceed the risks, does not appear to be particularly cost-effective. Opportunities to improve the cost-effectiveness of hypertension management lie in 1) avoidance of patient mislabeling by careful documentation of blood pressures on multiple occasions in the office and during usual activities outside the office before the diagnosis is made and treatment is begun; 2) efforts to increase adherence to scheduled visits and medication regimens; 3) attempts to step-down dosages or discontinue medications after periods of good blood pressure control; 4) explicit consideration of costs, as well as benefits, in decisions on the needed frequency of office visits, choice of medications, and use of laboratory tests; and 5) efforts to improve practice efficiency. Future practice guidelines for hypertension management should take these factors into account and should make trade-offs between benefits, risks, and costs explicit for specific types of patients.